Core Insights - Lexicon Pharmaceuticals has successfully completed the End-of-Phase 2 meeting with the FDA for pilavapadin, which is advancing into Phase 3 development for diabetic peripheral neuropathic pain (DPNP) [1][2] - The FDA raised no objections to the Phase 3 program, which will include two placebo-controlled studies comparing a 10 mg daily dose of pilavapadin to placebo [1][2] Company Overview - Lexicon Pharmaceuticals is a biopharmaceutical company focused on pioneering medicines that transform patients' lives, utilizing its Genome5000™ program to study nearly 5,000 genes and identify over 100 protein targets with therapeutic potential [4] - The company has a pipeline of drug candidates in various stages of development, targeting conditions such as neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity, and metabolism [4] Product Information - Pilavapadin is a once-daily, orally delivered small molecule inhibitor of AAK1, designed to treat neuropathic pain without affecting opiate pathways [3] - Preclinical studies have shown that pilavapadin penetrates the central nervous system and reduces pain behavior in neuropathic pain models [3]

Core Insights - Lexicon Pharmaceuticals announced new data on pilavapadin's effectiveness in reducing neuropathic pain in preclinical models of chemotherapy-induced peripheral neuropathy (CIPN) and multiple sclerosis (MS) at the NeuPSIG 2025 conference [1][2] - The findings emphasize the significance of AAK1 inhibition in pain signaling modulation, suggesting potential applications for pilavapadin beyond diabetic peripheral neuropathic pain (DPNP) [2][3] Company Overview - Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing innovative medicines through its Genome5000™ program, which has identified over 100 protein targets with therapeutic potential [5] - The company has a pipeline that includes drug candidates in various stages of development for conditions such as neuropathic pain, hypertrophic cardiomyopathy (HCM), and obesity [5] Product Information - Pilavapadin is a selective, investigational small molecule inhibitor of AAK1, designed for once-daily oral administration, which targets pain signaling without affecting opiate pathways [3][4] - The drug has received Fast Track designation from the U.S. FDA for its development in DPNP [4]